A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer

by | Dec 30, 2025 | Clinical Trials | 0 comments

​ Conditions: Advanced Lung Cancer

Interventions: Drug: JS212 for Injection; Drug: JS207 for Injection; Drug: Toripalimab; Drug: JS213 for Injection

Sponsors: Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting Conditions: Advanced Lung Cancer
Interventions: Drug: JS212 for Injection; Drug: JS207 for Injection; Drug: Toripalimab; Drug: JS213 for Injection
Sponsors: Shanghai Junshi Bioscience Co., Ltd.
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *